facebook twitter youtube
News archive
Recent news


Data on real-world efficacy outcomes for 2000 Patients with AL amyloidosis was presented at this year’s American Society of Haematology Annual Meeting (ASH). ASH was held virtually from 5 to 8 December.

This study, developed by the European Myeloma Network (EMN), shows therapeutic options for AL amyloidosis have changed considerably over time. After 2010, bortezomib, cyclophosphamide and dexamethasone (CyBorD) became the prominent first-line treatment, reducing the proportion of patients not achieving a response by 23%. Early diagnosis is still an unmet need, and improved therapies are essential.

Myeloma Patients Europe interviewed Dr Paolo Milani, Amyloidosis Research and Treatment Center, University Hospital San Matteo in Pavia, Italy, to analyse the results of this research. Watch the video below.




Keep an eye out for the interview MPE will published with Dr Pieter Sonneveld, president of the EMN, in which Dr Sonneveld also comments the results of this study.

Recent news

» Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosis

» Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.